BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24978034)

  • 1. Co-inhibitory pathways and their importance in immune regulation.
    Murakami N; Riella LV
    Transplantation; 2014 Jul; 98(1):3-14. PubMed ID: 24978034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
    Kumar P; Bhattacharya P; Prabhakar BS
    J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT; Bluestone JA
    Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTLA-4: From mechanism to autoimmune therapy.
    Hosseini A; Gharibi T; Marofi F; Babaloo Z; Baradaran B
    Int Immunopharmacol; 2020 Mar; 80():106221. PubMed ID: 32007707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
    Guram K; Kim SS; Wu V; Sanders PD; Patel S; Schoenberger SP; Cohen EEW; Chen SY; Sharabi AB
    Front Immunol; 2019; 10():491. PubMed ID: 30936880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orchestrating immune check-point blockade for cancer immunotherapy in combinations.
    Perez-Gracia JL; Labiano S; Rodriguez-Ruiz ME; Sanmamed MF; Melero I
    Curr Opin Immunol; 2014 Apr; 27():89-97. PubMed ID: 24485523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PD-1-PD-L pathway in immunological tolerance.
    Okazaki T; Honjo T
    Trends Immunol; 2006 Apr; 27(4):195-201. PubMed ID: 16500147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.
    Carreno BM; Collins M
    Annu Rev Immunol; 2002; 20():29-53. PubMed ID: 11861596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulatory and Inhibitory Co-signals in Autoimmunity.
    Okazaki T; Okazaki IM
    Adv Exp Med Biol; 2019; 1189():213-232. PubMed ID: 31758536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases.
    Prud'homme GJ; Piccirillo CA
    J Autoimmun; 2000 Feb; 14(1):23-42. PubMed ID: 10648114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting lymphocyte co-stimulation: from bench to bedside.
    Felix NJ; Suri A; Salter-Cid L; Nadler SG; Gujrathi S; Corbo M; Aranda R
    Autoimmunity; 2010 Nov; 43(7):514-25. PubMed ID: 20429850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-PD-1 antibody: basics and clinical application].
    Tanaka Y; Okamura H
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1145-9. PubMed ID: 24047772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of co-inhibitory signals driven by CTLA-4 in immune system].
    Olive D; le Thi S; Xerri L; Hirsch I; Nunès JA
    Med Sci (Paris); 2011 Oct; 27(10):842-9. PubMed ID: 22027421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the PD-1 pathway in autoimmunity and peripheral tolerance.
    Fife BT; Pauken KE
    Ann N Y Acad Sci; 2011 Jan; 1217():45-59. PubMed ID: 21276005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death-1 is required for systemic self-tolerance in newly generated T cells during the establishment of immune homeostasis.
    Thangavelu G; Parkman JC; Ewen CL; Uwiera RR; Baldwin TA; Anderson CC
    J Autoimmun; 2011 May; 36(3-4):301-12. PubMed ID: 21441014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
    Ramsay AG
    Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of positive costimulatory molecules in transplantation and tolerance.
    Agarwal A; Newell KA
    Curr Opin Organ Transplant; 2008 Aug; 13(4):366-72. PubMed ID: 18685331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.